CircMYBL1 Suppressed Acquired Resistance to Osimertinib in Non-Small-Cell Lung Cancer

Lung cancer is one of the top five cancer types diagnosed globally, accounting for 11.4% of all cancer cases in 2020, and non-small cell lung cancer (NSCLC) accounts for approximately 80 –85% of cases [1]. Following the decoding of human cancer genome, new therapeutic strategies have emerged in recent years, including targeted therapy against driver mutations, and immunotherapy, which significantly improve patient outcomes. Epidermal growth factor receptor (EGFR) mutations are the most common actionable driver mutations found in patients with NSCLC, and are present in 10–30% of all NSCLC cases [2–4].
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research